Login to Your Account

Cellzome in $1.5B Deal with GSK for Kinase Inhibitors

By Nuala Moran

Wednesday, September 10, 2008
LONDON - Anglo/German kinase specialist Cellzome Inc., sealed a deal worth a headline value of £830 million (US$1.5 billion) with GlaxoSmithKline plc for the development of kinase inhibitors in the treatment of inflammatory diseases. (BioWorld Today)

To continue reading subscribe now to BioWorld Today

Learn More about BioWorld Today

Already a subscriber? Sign In or Buy now to activate your subscription